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Abstract
Apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) is 
silenced by promoter methylation in many types of tumors, yet ASC’s role in most cancers 
remains unknown. Here, we show that ASC is highly expressed in a model of medulloblastoma, 
the most common malignant pediatric brain cancer; ASC is also expressed in human 
medulloblastomas. Importantly, while ASC deficiency did not affect normal cerebellar 
development, ASC knock-out mice on the Smoothened (ND2:SmoA1) transgenic model of 
medulloblastoma exhibited a profound reduction in medulloblastoma incidence and a delayed 
tumor onset. A similar decrease in tumorigenesis with ASC deficiency was also seen in the 
hGFAP-Cre:SmoM2 mouse model of medulloblastoma. Interestingly, hyperproliferation of the 
external granule layer (EGL) was comparable at P20 in both the wildtype and ASC-deficient 
SmoA1 mice. However, while the apoptosis and differentiation markers remained unchanged at 
this age, proliferation makers were decreased, and the EGL was reduced in thickness and area by 
P60. This reduction in proliferation with ASC deficiency was also seen in isolated SmoA1 
cerebellar granule precursor cells in vitro, indicating that the effect of ASC deletion on 
proliferation was cell autonomous. Interestingly, ASC deficient SmoA1 cerebella exhibited 
disrupted expression of genes in the TGF-β pathway and increased level of nuclear Smad3. 
Together, these results demonstrate an unexpected role for ASC in Sonic hedgehog-driven 
medulloblastoma tumorigenesis, thus identifying ASC as a promising novel target for anti-tumor 
therapy.
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INTRODUCTION
Medulloblastoma, a tumor of cerebellar progenitors, is the most common malignant brain 
cancer in children1. During normal development, proliferation of progenitors in the 
cerebellum extends into the early postnatal period, as cerebellar granule neuron progenitors 
(CGNPs) undergo rapid division in the external granule layer (EGL), then differentiate and 
migrate to the internal granule layer (IGL)2. CGNPs proliferate in response to endogenous 
Sonic hedgehog (Shh; mouse), and mutations that activate SHH (human) signaling cause 
predisposition to medulloblastoma in humans with Gorlin Syndrome, and in genetically 
engineered mouse models1, 3. These models, which operate through either Patched deletion 
or insertion of constitutively active alleles of Smoothened (Smo), consistently implicate 
CGNPs as the cells of origin for Shh-driven medulloblastoma4, 5. Importantly, while 
advances in treatment have increased the survival of patients with medulloblastoma, 
mortality remains significantly high and debilitating cognitive and endocrine side effects 
result from current treatment regimens3. Thus, advancing the understanding of the genetic 
components of medulloblastoma tumorigenesis is needed to develop improved targeted 
therapies.
ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain; also 
known as TMS-1, target of methylation-induced silencing-1 and Pycard) is expressed in 
many human tissues, however, is silenced by promoter hypermethylation in many tumor 
types, including glioblastoma6, neuroblastoma7, breast cancer8, melanoma9, and lung 
cancer10. Ectopic ASC expression sensitizes pancreatic, breast, and colon cancer cells to 
apoptosis8, 11–15, while knocking down endogenous ASC inhibits cell death of osteosarcoma 
cells13, colon cells15, and breast epithelial cells16. Additionally, ASC is the adaptor protein 
of the inflammasome, a cytosolic complex that senses pathogen-associated molecules and 
subsequently responds by activating pro-inflammatory substrates, pro-interleukin-1β (pro-
IL-1β) and pro-IL-18, which recruit and activate immune cells17–19. Consistent with the 
expectation that ASC inactivation promotes tumorigenesis, ASC-deficiency has been shown 
to enhance polyp formation in a colitis-associated colon cancer mouse model20, 21. Together, 
these studies point to ASC as a functional tumor suppressor.
In this study, we examined the role of ASC in medulloblastoma using mouse models. Our 
results reveal the unexpected finding that ASC promotes tumorigenesis in medulloblastoma. 
ASC was highly expressed in these tumors and the genetic deletion of ASC markedly 
reduced proliferation, hyperplasia, and mortality. These findings identify a novel role for 
ASC in promoting tumorigenesis in medulloblastoma.
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ASC is highly expressed in medulloblastomas
To investigate the role of ASC in cerebellar development and medulloblastoma, we 
evaluated ASC expression during mouse cerebellum development. ASC protein levels were 
high in postnatal-day 7 (P7) cerebellum, which corresponds to the peak period of CGNP cell 
proliferation, and decreased with cerebellar maturation (Figure 1a). ASC is reported to 
enhance apoptosis upon expression and is often silenced via methylation in a variety of 
cancers8, 11–14. To determine whether ASC was also silenced in cancer of cerebellar origin, 
we examined ASC expression in medulloblastoma. We used the ND2:SmoA1 (SmoA1) 
mouse model of medulloblastoma which expresses an activated allele of Smo in CGNPs, 
resulting in CGNP hyperproliferation and tumor growth as a consequence of the constitutive 
activation of the Sonic hedgehog pathway5. In contrast to the reports in other cancer types, 
we unexpectedly detected high levels of ASC in medulloblastoma (Figure 1a). Also, ASC 
mRNA levels closely matched protein levels throughout development and in the tumor 
(Figure 1b). These data reveal the surprising observation that ASC is not subjected to 
silencing but is induced in a mouse model of medulloblastoma.
To investigate ASC expression in human medulloblastomas, we conducted in situ 
hybridization (ISH) on sections of a tissue microarray (TMA) from 11 classic, 3 
desmoplastic, and 1 large cell/anaplastic medulloblastomas obtained from 15 patients (8 
males and 7 females; ages 1–38, median age=15). Overall, the majority (60%) were positive 
for ASC, including 45.5% of classic tumors, 100% of desmoplastic tumors, and the large 
cell/anaplastic tumor (Table 1). Classic tumors exhibited a range of ASC expression, while 
all desmoplastic tumors were positive for ASC expression (Figure 1c). Examination of 
publicly available gene expression profiling data in the Oncomine database also reveals 
ASC to be expressed in human medulloblastomas, with significantly increased expression in 
desmoplastic versus classic tumors (Figure 1d)22, 23. Furthermore, a recent paper reported 
ASC amplification to be a frequent genetic event in the human medulloblastomas studied24. 
Together, these data indicate that ASC is expressed in a significant portion of human 
medulloblastomas.
ASC deficiency does not affect normal cerebellum development
To investigate whether ASC expression is important in medulloblastoma tumorigenesis, we 
first evaluated whether ASC deficiency affected normal cerebellar development. Cerebellar 
development occurs postnatally with rapid CGNP proliferation in the EGL peaking at P7. As 
CGNPs terminally differentiate into cerebellar granule neurons (CGNs), they migrate to the 
IGL to form the mature cerebellum by P202. We therefore compared cerebellar architecture 
of ASC+/+ and ASC−/− mice during this key developmental period. H&E staining revealed 
no differences in gross morphology between wild-type and ASC-deficient cerebella 
throughout development (Figure 1e). To specifically examine whether proliferation was 
altered by ASC deficiency, we compared expression of proliferation markers cyclin D2 and 
phospho-histone H3 (pH3) in ASC+/+ and ASC−/− P7 cerebellum. No differences in cyclin 
D2 levels and pH3 staining were observed between wild-type and ASC-deficient cerebella 
(Figures 1f and g).
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ASC deficiency suppresses SmoA1- and SmoM2-induced medulloblastoma
Next, to determine whether ASC deficiency affects medulloblastoma, we generated ASC+/+, 
ASC+/−, and ASC−/− SmoA1 mice and compared the time of tumor emergence in each 
group. In this Smo transgenic medulloblastoma model, signs of tumors typically emerge at 
3–8 months and precede death from the disease by only a few days; thus, once signs emerge, 
mice are in a moribund state5. Surprisingly, ASC deficiency conferred a striking reduction in 
tumor incidence and delay in tumor onset in the transgenic mice (Figure 2a). Overall tumor 
incidence by P300 was significantly reduced in mice lacking ASC: while 12 of 15 
ASC+/+;SmoA1 mice exhibited tumors, only 5 of 18 ASC−/−;SmoA1 mice developed 
medulloblastoma (Figure 2b). Additionally, ASC deficiency markedly delayed latency to 
tumor formation in ASC−/−;SmoA1 mice compared to ASC+/+;SmoA1 and ASC+/−;SmoA1 
mice (Figure 2a). ASC heterozygous mice also exhibited a delayed rate of tumorigenesis 
when compared to wild-type mice (Figure 2a).
To test whether ASC deficiency affects tumorigenesis in another model of medulloblastoma, 
we utilized the SmoM2 model. SmoM2 is a constitutively active Shh-driving Smo mutation 
discovered to aggressively induce medulloblastoma in mice by P2025–27. We generated 
ASC+/+, ASC+/−, and ASC−/− hGFAP-Cre:SmoM2 (SmoM2) mice and evaluated time to 
tumor emergence and moribund status. ASC deficiency markedly reduced tumorigenesis in 
the SmoM2 model, with loss of even one ASC allele extending survival (Figure 2c). While 
all mice developed medulloblastoma in this model, the average age at which mice became 
moribund was delayed in ASC heterozygous and knock-out mice (Figure 2d). Thus, ASC 
deficiency profoundly reduced tumorigenesis and extended survival in two distinct mouse 
models of medulloblastoma.
One of the known functions of ASC is that it is an adaptor protein for the inflammasome, a 
complex that, when triggered by intracellular signals, cleaves proinflammatory substrate 
pro-IL-1β into its active form17–19. IL-1β has been reported to have several functions 
promoting cancer28, although it has not been studied in medulloblastoma. To determine 
whether IL-1β is required for medulloblastoma development, we evaluated tumorigenesis in 
IL-1β deficient mice in the SmoA1 model. In contrast to our results with the loss of ASC, 
IL-1β deficiency did not affect medulloblastoma onset or incidence (Supplemental Figure 1).
To determine the point at which ASC deficiency blocks tumorigenesis in medulloblastoma, 
we compared wild-type and ASC-deficient SmoA1 cerebella at multiple time points during 
tumor development. In this tumor model, ectopic CGNP proliferation can be detected by 
P20 and progresses into tumor in adulthood. To examine whether ASC deficiency affects 
CGNP hyperproliferation during the pre-tumor stages (P20, P60), histological H&E stained 
sections of ASC+/+ and ASC−/− SmoA1 cerebella were compared. ASC−/−;SmoA1 cerebella 
exhibited equivalent ectopic CGNP proliferation and EGL architecture as seen in 
ASC+/+;SmoA1 mice at P7 and P20. However, by P60, ASC deletion significantly reduced 
the proportion and thickness of EGL in the cerebella (Figures 3a, b, and c). Thus, ASC 
deficiency did not block the initial stages of CGNP hyperproliferation but markedly 
diminished ectopic EGL in the cerebellum by P60.
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ASC deficient SmoA1 cerebella exhibit reduced proliferation
Tumorigenesis can be regulated by the balance of proliferation, differentiation, and 
apoptosis. We sought to determine which factors were responsible for the requirement of 
ASC in Shh-driven medulloblastoma. To test whether proliferation was altered in the ASC 
knock-out cerebella in the SmoA1 medulloblastoma model, we performed Western blot 
analysis for cyclin D2 and immunohistochemistry for the mitotic marker pH3 in wild-type 
and ASC-deficient SmoA1 mice. Cyclin D2 levels were unchanged at P7, but were 
strikingly reduced by P60, at which point cyclin D2 levels were virtually undetectable in the 
ASC-deficient mice but were sustained in the wild-type mice on the SmoA1 background 
(Figure 3d). Thus, even though gross reduction in hyperplasia was not detected by P20 in the 
ASC−/−;SmoA1 cerebella, markers of proliferation showed an emerging trend of reduction 
at this time point. To directly test whether ASC expression affected proliferation of the 
CGNPs in the EGL, we conducted pH3 immunohistochemistry. Consistent with the 
reduction in cyclin D2 levels, pH3 staining was reduced by nearly 50 % at P20, revealing a 
lower mitotic frequency in the EGL with ASC deletion (Figures 3e and f). These results 
identify a role for ASC in regulating ectopic proliferation of CGNPs in medulloblastoma in 
vivo.
We next examined whether the effect of ASC on proliferation of CGNPs in this tumor 
model was cell autonomous. CGNPs from ASC+/−;SmoA1 and ASC−/−;SmoA1 mice were 
isolated and maintained for two days in vitro. Western blot analysis revealed that ASC 
deficiency reduced the proliferation marker cyclin D2 even in these isolated tumor cells 
(Figure 3g). These data suggest a cell intrinsic effect of ASC on CGNP proliferation in the 
SmoA1 model. However, we cannot exclude the possibility that ASC deficiency could also 
affect stromal signals to modulate CGNP proliferation in vivo.
Previous studies have reported a decrease in proliferation with ASC deficiency in stimulated 
CD4+ and CD8+ T cells, splenocytes, and lymph node cells29–31. However, other studies 
have reported either no difference in proliferation of ASC knock-out splenocytes or an 
increase in proliferation with ASC deletion in keratinocytes32, 33. Together, these data point 
to a complex role for ASC in regulating cell proliferation, with our results showing that ASC 
deficiency markedly reduces proliferation in medulloblastoma.
Numerous studies have shown that ASC is proapoptotic when overexpressed in cancer cell 
lines8, 11–15. Furthermore, knockdown of endogenous ASC reduces apoptosis of breast 
epithelial cells16, colon cancer cells15, and osteosarcoma cells13. We examined whether 
ASC altered apoptosis or differentiation during tumorigenesis and found no statistical 
differences in the differentiation marker NeuN or the apoptosis marker cleaved caspase-3 
between wild-type and ASC-deficient P20 SmoA1 EGL (Figures 3e and f). Likewise, other 
groups have found no difference in apoptosis with loss of endogenous ASC in keratinocytes 
or splenocytes31, 33. Together, these results identify reduced proliferation as the likely key 
factor suppressing medulloblastoma tumorigenesis in ASC deficient mice.
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ASC deficient SmoA1 cerebella exhibit altered TGF-β pathway gene expression and 
increased nuclear Smad3
To determine the mechanism by which ASC deficiency inhibits proliferation in 
medulloblastoma, we conducted a microarray analysis comparing gene expression of 
ASC−/− versus ASC+/+ cerebella on the SmoA1 background. We focused on P20 because 
the differences in the ASC−/− and ASC+/+ cerebellar phenotypes begin to emerge at this 
timepoint. Microarray data are available in Gene Expression Omnibus under the accession 
number GSE48682. Microarray analysis revealed only 3 genes (in addition to ASC) to be 
differentially expressed between ASC−/− and ASC+/+ SmoA1 cerebellum at this timepoint 
(Table 2). The fact that only a small number of genes were identified to be differentially 
expressed is not surprising as differences in the tumor phenotype are just emerging at the 
P20 timpoint. Of the 3 differentially-expressed genes identified, Tgfb1i1 (transforming 
growth factor beta-1-induced transcript 1), which was 2.5 fold higher in the ASC knock-out 
samples, is known to be upregulated with TGF-β (transforming growth factor-β)34. 
Interestingly, Tgfb1i1 (also known as Hic-5) has been reported to inhibit cell proliferation 
when overexpressed in cells35, 36. We next examined whether the TGF-β pathway was 
altered in the absence of ASC. Indeed, quantitative PCR analysis confirmed dysregulation of 
TGF-β pathway genes in the knock-out, with Tgfb1i1 significantly upregulated while the 
TGF-β inhibitor Tgif1 was significantly downregulated in ASC-deficient P20 SmoA1 mice. 
Furthermore, cell cycle genes cyclin D2 and Cdk2 were decreased in the ASC knock-out 
SmoA1 cerebella (Figure 4a).
Dysregulation of the TGF-β pathway has been recognized in a subgroup of 
medulloblastomas37–39. To investigate whether TGF-β signaling is altered in ASC−/− 
transgenic cerebella, we evaluated cellular phospho-Smad3 localization using 
immunohistochemistry. Interestingly, we found a greater percentage of cells with nuclear 
Smad3 in the ASC deficient transgenic cerebella (Figure 4b). These data reveal an 
unexpected link between ASC and the TGF-β pathway whereby ASC deficient cerebella 
exhibit altered TGF-β pathway gene expression and increased nuclear Smad3 in a mouse 
model of medulloblastoma.
Interestingly, TGF-β activation has a dual role in cancer, as the pathway promotes epithelial-
mesenchymal transition and metastasis, but early TGF-β activation restricts tumorigenesis 
by inducing apoptosis and reducing cell proliferation40, 41. The dichotomous effects of the 
TGF-β pathway are evident in medulloblastoma. One group found disruption of TGF-β 
pathway genes in one of four subsets of medulloblastoma, namely deletion of TGF-β 
inhibitors and amplification of Type II activin receptors and TGFBR137. In contrast, we 
observed an association between increased TGF-β pathway gene expression and signaling 
and decreased CGNP proliferation in the ASC knock-out SmoA1 P20 cerebella. Consistent 
with our results, increasing TGF-β signaling with BMP2/4 addition or Smad5 
overexpression in the presence of Shh stimulation reduces CGNP proliferation42, 43. 
Furthermore, increased nuclear Smad3 in SHH-related human medulloblastomas is 
correlated with a more favorable prognosis38.
Knight et al. Page 6













While these results in medulloblastoma identify a clear role of ASC in promoting 
tumorigenesis, ASC has also been described as a tumor suppressor in specific cancer 
models. ASC suppresses tumorigenesis in a colitis-associated colon cancer mouse model, 
where ASC deficiency enhanced polyp formation and clinical exacerbation, resulting in 
reduced survival20, 21. In a model of squamous cell carcinoma, selective deletion of ASC in 
bone marrow derived macrophages suppressed tumor number but ASC ablation in 
keratinocytes promoted tumorigenesis33. When ASC was deleted from the whole animal, 
ASC knock-out mice showed no differences from wild-type in tumor susceptibility33. In 
melanoma, a recent study found that ASC-deficient metastatic melanoma cells injected into 
nude mice displayed reduced tumor growth as compared to wild-type tumor cell 
implantation. In contrast, ASC-deficient primary melanoma implants hastened tumor growth 
versus wild-type controls44. Thus, the role of ASC in carcinogenesis appears to depend on 
the cancer, cell type, and stage of cancer progression.
In summary, our results identify a critical function of ASC in driving proliferation and 
tumorigenesis in Shh pathway-driven models of medulloblastoma. Improved therapeutics 
for this cancer are needed due to the high mortality and devastating side effects of current 
treatment. Our results show that targeting ASC may be a promising strategy for preventing 
tumor progression of medulloblastoma.
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ASC is expressed in cerebellum and medulloblastoma but ASC deficiency does not affect 
normal cerebellum development. (a) Western blot analysis of cerebellar lysates reveals ASC 
expression during normal cerebellum development and increased ASC expression in 
medulloblastoma. (Tumor sample shown is from postnatal 101-day-old, P101, mouse.) 
Densitometric quantification reveals ASC levels are increased in medulloblastomas. Data 
are mean of four separate experiments +/− s.e.m. analyzed by Student’s t-test (P=0.014, 
0.019) and one-way ANOVA (P=0.029); n=3–4 per group. ASC levels are normalized to 
loading controls and average P60 levels were set to 1.0 for each experiment. *P<0.05. 
Cerebella were collected at specified ages and lysates were probed with antibodies against 
ASC (Alexis Biochemicals, Lausen, Switzerland; Adipogen, San Diego, CA, USA), Cyclin 
D2 (CD2; Cell Signaling, Danvers, MA, USA) and α-tubulin (Sigma-Aldrich, St. Louis, 
MO, USA). (b) Quantitative RT-PCR analysis demonstrates ASC mRNA decreases during 
normal cerebellum development and is induced in medulloblastoma. Cerebella were 
collected at the ages specified (n=4–6 per age). Tumors were collected at an average age of 
P138 (P101-P205; n=8). qRT-PCR was conducted similarly as previously described45, using 
primers Pycard-FW: 5′-GACCAGCACAGGCAAGCA-3′, Pycard-Rev: 5′-
TCCAGCACTCCGTCCACTTC-3′, Gapdh-FW: 5′-TGTGTCCGTCGTGGATCTGA-3′, 
and Gapdh-Rev: 5′-CCTGCTTCACCACCTTCTTGA-3′, and normalizing to GAPDH 
levels. Data are mean ± s.e.m analyzed by the Mann-Whitney test. Experiments were done 
in triplicate four times. **P<0.01; *P<0.05. (c) RNA in situ hybridization (ISH) of human 
medulloblastoma tissue microarray sections for (A) DapB (negative control), (B) PPIB 
(positive control), and four representative samples where ASC expression was scored as (C) 
0 (no signal), (D) 1 (rare signal), (E) 2 (scattered signal) or (F) 3 (ubiquitous signal). RNA 
ISH was performed and ASC expression was quantified as described in Table 1. The scatter 
plot shows mean ASC expression score and s.e.m. for classic and desmoplastic tumors. The 
average score was 1.3 for classic tumors (n=11), 2.3 for desmoplastic tumors (n=3), and 2.0 
for large cell/anaplastic medulloblastoma (n=1). The difference between the desmoplastic 
and classic groups was not significant (P=0.12; Student’s t-test). No correlation between 
ASC score and age or gender was observed. Scale bar represents 10 μm. (d) Oncomine 
analysis of independent gene profiling studies, with data from Kool et al.22 and Fattet et 
al.23 was used to compare ASC mRNA expression levels in classic versus desmoplastic 
human primary medulloblastomas. Each dataset had equivalent proportions of desmoplastic 
tumors (22%) and classic tumors (78%) and F-test analysis determined the datasets did not 
have unequal variance (F=0.054). Data are medians with 95% confidence intervals for ASC 
mRNA in the combined datasets (*P=0.047, two-tailed t-test; n=74 classic; n=21 
desmoplastic). Correction for potential technical bias between datasets, by adjusting values 
to make each dataset mean equal zero, yielded similar results (P=0.025; data not shown). (e) 
Representative images of H&E stained sagittal sections of ASC+/+ and ASC−/− cerebella at 
specified ages show no differences in gross cerebellar architecture with development 
between genotypes (n=3–8 per group). Scale bars represent 1 mm and 200 μm (inset). (f) 
ASC+/+ and ASC−/− cerebellar lysates at specified ages were immunoblotted as described 
above. (g) Immunohistochemistry (IHC) for phospho-histone H3 (pH3; Cell Signaling) in 
P7 ASC+/+ and ASC−/− sagittal cerebellar sections. Quantitative comparison of cells 
expressing pH3 in ASC+/+ and ASC−/− EGL (n=3–7 per group). The EGL region was 
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manually annotated using Aperio ImageScope V12 and analyzed with Aperio Nuclear V9 
Algorithm (Aperio Technologies, Inc., Vista, CA, USA). The data represent mean +/− s.e.m. 
analyzed by Student’s t-test. Scale bar represents 200 μm.
Knight et al. Page 13














ASC deficiency suppresses medulloblastoma tumorigenesis in the SmoA1 and SmoM2 
mouse models. (a) Kaplan-Meier analysis of ASC+/+;SmoA1 mice (n=15), ASC+/−;SmoA1 
mice (n=34), and ASC−/−;SmoA1 mice (n=18) reveals a significant difference in tumor 
incidence with ASC expression (P=0.0019; Log-Rank test). ASC deficiency significantly 
decreased tumor frequency and increased tumor latency when compared to ASC+/+;SmoA1 
(P=0.0004; Log-Rank test) and ASC+/−;SmoA1 mice (P=0.0077; Log-Rank test). (P=0.1108 
between ASC+/−;SmoA1 and ASC+/+;SmoA1 mice; Log-Rank test.) (b) Overall incidence 
of medulloblastoma by P270 is reduced in ASC−/−;SmoA1 versus ASC+/+;SmoA1 
(P=0.0049; Fisher’s exact test) and ASC+/−;SmoA1 (P=0.0088; Fisher’s exact test) mice; 
**P<0.01. (c) Kaplan-Meier analysis of ASC+/+;SmoM2 mice (n=4), ASC+/−;SmoM2 mice 
(n=9), and ASC−/−;SmoM2 mice (n=6) reveals a significant difference in tumorigenesis with 
ASC expression (P= 0.0004; Log-Rank test). ASC+/+;SmoM2 mice displayed shorter tumor 
latency than either ASC−/−;SmoM2 (P=0.0025; Log-Rank test) or ASC+/−;SmoM2 
(P=0.0003; Log-Rank test) mice. (P=0.732 between ASC+/−;SmoM2 and ASC−/−;SmoM2 
mice; Log-Rank test.) (d) The average age mice become moribund is increased with ASC 
deficiency in ASC−/−;SmoM2 mice and ASC+/−;SmoM2 mice. **P=0.004; *P=0.025 
(Student’s t-test).
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ASC deficiency reduces proliferation in the SmoA1 cerebella in vivo and in Smo transgenic 
CGNPs in vitro. (a) Representative H&E stained sagittal sections of ASC+/+;SmoA1 and 
ASC−/−;SmoA1 cerebella at specified ages reveals reduced EGL with ASC deficiency. Scale 
bars represent 1 mm and 200 μm (inset). (b) EGL area in proportion to cerebellum (CB) area 
and (c) maximum EGL thickness were manually quantified using Aperio ImageScope V12 
annotations (Aperio Technologies, Inc.) in ASC+/+;SmoA1 and ASC−/−;SmoA1 cerebella at 
the specified ages (n=3–7 per group). ASC deficiency reduced EGL area proportion and 
maximum EGL thickness in P60 cerebella. **P=0.0049;*P=0.045 (Student’s t-test). ASC 
status significantly altered both EGL proportion and thickness over all timepoints (P=0.035 
and P=0.04 respectively; two-way ANOVA). (d) Western blot analysis of ASC+/+;SmoA1 
and ASC−/−;SmoA1 cerebellar lysates at the specified ages as described above. 
Densitometric quantification reveals Cyclin D2 (CD2) levels are reduced at P20 (P=0.12) 
and P60 (***P=0.00039) with ASC deficiency. Data are mean +/− s.e.m. analyzed by 
Student’s t-test (n=5–7 per group). (e) Representative IHC for pH3, NeuN (Millipore, 
Billerica, MA, USA), and cleaved caspase-3 (CC3; Biocare Medical, Concord, CA, USA) of 
P20 ASC+/+;SmoA1 and ASC−/−;SmoA1 cerebella. Scale bar represents 200 μm. (f) 
Quantification of positively stained cells in the P20 EGL reveals a significant decrease in 
pH3 staining with ASC deficiency. *P= 0.017. The data represent mean +/− s.e.m. analyzed 
by Student’s t-test (n=3–5 per group). Quantification was performed as described in Figure 
1f. (g) Western blot analysis shows a reduction in cyclin D2 levels with ASC deficiency in 
isolated SmoA1 cerebellar granule precursor cells. CGNPs were isolated from 
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ASC+/−;SmoA1 and ASC−/−;SmoA1 mice similarly to previously described46, with cells 
cultured for 48 hours in serum-free conditions. Results shown are from two independent sets 
of ASC+/−;SmoA1 and ASC−/−;SmoA1 mice.
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ASC deficiency alters the TGF-β pathway in SmoA1 cerebella. (a) Quantitative RT-PCR 
analysis reveals several genes in the TGF-β pathway are differentially expressed in ASC−/− 
versus ASC+/+ P20 SmoA1 cerebella. qRT-PCR was conducted similarly as previously 
described45, using primers Tgfb1-FW: 5′-ACCATGCCAACTTCTGTCTG-3′ and Tgfb1-
Rev: 5′-CGGGTTGTGTTGGTTGTAGA-3′; Tgfb1i1-FW: 5′-
CCTTTTCGCCCCGAGTGCTA-3′ and Tgfb1i1-Rev: 5′-
CGGATGGGTTGGTTACAGAAG-3′; Tgif1-FW: 5′-GAGGATGAAGACAGCATGGA-3′ 
and Tgif1-Rev: 5′-TTCTCAGCATGTCAGGAAGG-3′; Cyclin D2-FW: 5′-
TCGATGATTGCAACTGGAAG-3′ and Cyclin D2-Rev: 5′-
AGAGCTTCGATTTGCTCCT-3′; Cdk2-FW: 5′-TCATGGATGCCTCTGCTCTCAC-3′ 
and Cdk2-Rev: 5′-TGAAGGACACGGTGAGAATGGC-3′; Gapdh-FW: 5′-
TGTGTCCGTCGTGGATCTGA-3′ and Gapdh-Rev: 5′-
CCTGCTTCACCACCTTCTTGA-3′, and normalizing to GAPDH levels. Data are mean ± 
s.e.m analyzed by the Mann-Whitney test. Experiments were done in triplicate three to five 
times per gene (n=3–5 per genotype). **P<0.01; *P<0.05. (b) Quantification of Smad3 IHC 
(Abcam, Cambridge, MA, USA) in P20 ASC+/+;SmoA1 and ASC−/−;SmoA1 cerebella 
reveals an increase in cells positive for nuclear Smad3 with ASC deletion. 50 μm wide 
bands of the outer internal granule layer and the molecular layer were manually annotated 
using Aperio ImageScope V12 and analyzed with Aperio Nuclear V9 Algorithm (Aperio 
Technologics, Inc.), excluding Purkinje cells from analysis using cell size parameters. 
*P<0.05. The data represent mean +/− s.e.m. analyzed by Student’s t-test (n=3 per group).
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Table 1
Summary of ASC expression in human medulloblastomas
RNA in situ hybridization (ISH) of human medulloblastoma TMA sections was conducted for ASC with the 
RNAscope 2.0 HD Reagent Kit (BROWN) (Advanced Cell Diagnostics, Inc., Hayward, CA, USA) according 
to the manufacturer’s instructions. Each tumor was scored for ASC signal as 0 (no signal), 1 (rare signal), 2 
(scattered signal) or 3 (ubiquitous signal), with scores of at least 1.5 defined as positive for ASC expression. 
Samples were scored independently by two blinded observers, including one neuropathologist (RM), and any 
discrepant interpretations were resolved by consensus review. The formalin-fixed paraffin-embedded human 
tumor block was obtained from UNC Hospitals with approval by the Internal Review Board.
ASC Positive ASC Negative Total
Classic 5 6 11
Desmoplastic 3 0 3
Large cell/anaplastic 1 0 1
Overall (%) 9 (60) 6 (40) 15 (100)
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Table 2
Summary of genes differentially expressed with ASC deficiency in P20 SmoA1 cerebella
Total RNA was purified from P20 SmoA1 cerebella (n=5, ASC+/+;SmoA1; n=4, ASC−/−; SmoA1) and 1000 
ng RNA per sample was labeled using the Quick Amp Labeling Kit (Agilent Technologies, Sugar Land, TX, 
USA) and hybridized on two-color whole mouse genome 4×44K microarrays (Agilent Technologies). 1000 ng 
RNA from pooled P16 wild-type cerebella was amplified and labeled with Cy3 as a reference for each sample. 
Raw data was processed and analyzed by GeneSpring GX Version 11.0 (Agilent Technologies). Genes with a 
corrected P value <0.05 following unpaired t-test and Benjamini and Hochberg false discovery rate procedure 
were considered differentially expressed.
Symbol RefSeq Gene Name Fold change P value
Up-regulated
Gdpd3 NM_024228 Glycerophosphodiester phospho-diesterase domain containing 3 +5.914 0.0268
Tgfb1i1 NM_009365 Transforming growth factor beta 1 induced transcript 1 +2.504 0.0494
Down-regulated
Sec23ip NM_001029982 Sec23-interacting protein −1.492 0.0268
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